GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SeaStar Medical Holding Corp (NAS:ICU) » Definitions » Debt-to-EBITDA

ICU (SeaStar Medical Holding) Debt-to-EBITDA : -0.03 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is SeaStar Medical Holding Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SeaStar Medical Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.57 Mil. SeaStar Medical Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. SeaStar Medical Holding's annualized EBITDA for the quarter that ended in Dec. 2024 was $-18.69 Mil. SeaStar Medical Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SeaStar Medical Holding's Debt-to-EBITDA or its related term are showing as below:

ICU' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.76   Med: -0.36   Max: 2.02
Current: -0.02

During the past 5 years, the highest Debt-to-EBITDA Ratio of SeaStar Medical Holding was 2.02. The lowest was -0.76. And the median was -0.36.

ICU's Debt-to-EBITDA is ranked worse than
100% of 284 companies
in the Biotechnology industry
Industry Median: 1.395 vs ICU: -0.02

SeaStar Medical Holding Debt-to-EBITDA Historical Data

The historical data trend for SeaStar Medical Holding's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeaStar Medical Holding Debt-to-EBITDA Chart

SeaStar Medical Holding Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
2.02 -0.60 -0.76 -0.36 -0.02

SeaStar Medical Holding Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.08 -0.25 - -0.03

Competitive Comparison of SeaStar Medical Holding's Debt-to-EBITDA

For the Biotechnology subindustry, SeaStar Medical Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SeaStar Medical Holding's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SeaStar Medical Holding's Debt-to-EBITDA falls into.


;
;

SeaStar Medical Holding Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SeaStar Medical Holding's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.574 + 0) / -24.583
=-0.02

SeaStar Medical Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.574 + 0) / -18.688
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


SeaStar Medical Holding  (NAS:ICU) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


SeaStar Medical Holding Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SeaStar Medical Holding's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SeaStar Medical Holding Business Description

Traded in Other Exchanges
N/A
Address
3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Executives
Kevin Chung officer: Chief Medical Officer C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Heel Kenneth Van director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Richard D. Russell director 3201 W BAY VISTA AVE, TAMPA FL 33611
Bruce M. Rodgers director 302 KNIGHTS RUN AVE., STE. 1000, TAMPA FL 33602
Andres Lobo director C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Caryl Baron officer: See Remarks C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Eric Schlorff director, officer: Chief Executive Officer C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Rick Barnett director C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Allan Collins director C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Dow Employees' Pension Plan Trust 10 percent owner 2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Union Carbide Employees' Pension Plan Trust 10 percent owner 2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Martin A Traber director 100 N TAMPA STREET, SUITE 2700, TAMPA FL 33602
Lm Funding America, Inc. 10 percent owner 1200 WEST PLATT STREET, SUITE 100, TAMPA FL 33606
Craig E Burson director 400 N. PARK AVENUE, UNIT 10B, BRECKENRIDGE CO 80424
Bruce H Bennett director 3929 ARLINGTON DRIVE, PALM HARBOR FL 34685